Dyslipidaemia: PCSK9 antibodies: A dividend of the genomics revolution

Nature Reviews Cardiology

Volumn 10, Issue 11, 2013, Pages 618-619

  Davidson, Michael H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MIPOMERSEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY PCSK9; PLACEBO; TORCETRAPIB; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; GENOMICS; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; ISCHEMIC HEART DISEASE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; AZETIDINES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; PROPROTEIN CONVERTASES;

EID: 84886722004     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2013.139     Document Type: Short Survey

References (10)

1. Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
2. Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165 (2005).
3. Qian, Y. W. et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J. Lipid Res. 48, 1488-1498 (2007).
4. Steinberg, D. & Witztum, J. L. Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc. Natl Acad. Sci. USA 106, 9546-9547 (2009).
5. Fasano, T., Sun, X. M., Patel, D. D. & Soutar, A. K. Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells. Atherosclerosis 203, 166-171 (2009).
6. Lambert, G., Sjouke, B., Choque, B., Kastelein, J. J. & Hovingh, G. K. The PCSK9 decade. J. Lipid Res. 53, 2515-2524 (2012).
7. Giugliano, R. P. et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380, 2007-2017 (2012).
8. Desai, N. R. et al. AMG 145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 128, 962-969 (2013).
9. Kathiresan, S. Lp(a) lipoprotein redux-from curious molecule to causal risk factor. N. Engl. J. Med. 361, 2573-2574 (2009).
10. Nordestgaard, B. G. et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 31, 2844-2853 (2010).